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Abstract
Background: Hepatitis C virus (HCV) infection is common in prisoner populations, particularly those with a history
of injecting drug use (IDU). Previous studies of HCV incidence have been based on small case numbers and have
not distinguished risk events in prison from those in the community.
Methods: HCV incidence was examined in a longitudinal cohort of 488 Australian prisoners with a history of IDU
and documented to be seronegative within 12 months prior to enrolment. Inmates were tested for anti-HCV
antibodies and viremia, and interviewed about demographic and behavioral risk factors for transmission.
Results: The cohort was predominantly male (65%) with high rates of prior imprisonment (72%) and tattooing (73%),
as well as longstanding IDU (mean 8.5 years). Ninety-four incident HCV cases were identified (incidence 31.6 per 100
person years). Independent associations were observed between incident infection and prior imprisonment (p = 0.02)
and tattooing (p = 0.03), and surprisingly also with methadone maintenance treatment (MMT) (p <0 . 0 0 1 ) .
Conclusions: High rates of new HCV infection were found in this prisoner cohort reflecting their substantive risk
behavior profile, despite having remained uninfected for many years. The association with MMT is challenging and
highlights the need for better understanding of prison-specific HCV transmission risks, as well as the uptake and
effectiveness of prevention programs.
Background
Hepatitis C (HCV) is primarily transmitted through par-
enteral exposure to contaminated blood. Injecting drug
use (IDU) with sharing of injecting equipment accounts
for the majority of new infections in developed countries
[1]. HCV has infected 2.2% of the world’s population [2],
with prevalence rates of up to 91% documented in IDU
populations with injecting histories of more than five
years, and incidence rates as high as 45.8 per 100 per-
son-years recorded in new IDU [3,4].
Very close relationships exist between illicit drug use,
HCV infection, and imprisonment [5]. Injecting drug
users (IDUs) have high rates of imprisonment predomi-
nantly due to the criminalization of their drug use, and
the tendency to fund some drug use through crime. For
instance, almost half of all prison inmates in Australia
report a lifetime history of IDU and approximately 70%
have been incarcerated for drug-related crimes [6].
Imprisonment is an independent risk factor for HCV
infection in community-based IDUs [7,8]. Estimates of
the prevalence of IDU in prison have ranged from 11%
in Canada [9] to 53% in Scotland [10].
Among IDU prisoners, HCV incident case rates range
widely from less than 6% up to 38% per annum [11,12].
It should be noted that these estimates were all based
on small numbers of incident cases (range: 1-14 cases;
mean 7), and were largely unable to separately define
the case rates associated with transmission events in
prison from those occurring shortly prior to imprison-
ment or during periods of release to freedom. Incident
H C Vi n f e c t i o ni np r i s o ni n m a t e sh a sb e e nc o r r e l a t e d
with several demographic and behavioral risk factors,
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any medium, provided the original work is properly cited.including age, female gender, tattooing, as well as speci-
fic injecting behaviors including sharing of needles and
syringes and heroin as a drug of choice [13-18]. A
recent meta-analysis of six published studies of HCV
incidence in prison inmates [11,13,15,18-20] reported
that the risk of HCV infection was eight times greater in
IDU prisoners than in non-IDU prisoners [21].
The aims of this study were to determine HCV inci-
dence amongst an IDU prisoner cohort delineating likely
in-prison from community transmission events, and to
carry out a detailed examination of demographic and
behavioral risk factors associated with HCV transmission.
Methods
Subjects
From September 2005 to May 2009 adult prison inmates
were recruited at 19 of 30 correctional centres housing
adult male or females in New South Wales, Australia as
part of the Hepatitis C Incidence and Transmission in
Prisons Study (HITS-II) prospective cohort. The data
reported here were derived from the enrolment inter-
view and laboratory testing for anti-HCV antibodies and
HCV RNA.
Male and female inmates were recruited into the HITS
cohort by several methods, including promotional flyers
at prison clinics, word of mouth amongst inmates, and
by research nurses directly approaching inmates who had
a recent negative anti-HCV antibody test result in their
prison medical record (of whom less than 10% declined
enrolment). Subjects were enrolled if they met all of the
following inclusion criteria: 18 years of age or older; self-
reported lifetime history of IDU; a documented negative
anti-HCV antibody test result within the previous 12
months (performed either in prison or in the community,
and sighted in the prison medical file); and adequate Eng-
lish to provide both valid written informed consent and
to participate in the study interview. Subjects were
excluded if they were forensic inmates (i.e. those unable
to stand trial due to mental illness), or had HIV infection,
chronic hepatitis B infection, or were pregnant at the
time of enrolment (as these parameters impacted on
immunological studies which form part of the study pro-
tocol reported elsewhere - Cameron B et al., manuscript
in preparation). All subjects provided written, informed
consent and received a $A10 payment upon completion
of the interview and initial blood sampling. The consent
form included specific details about the risk factors for
acquiring hepatitis C and a listing of hepatitis services for
contact should further information be required, as well as
a provision for informing inmates of their HCV serology
and virology test results and post-test counselling, with
referral to a hepatitis clinical service for further assess-
ment and care if the results suggested HCV infection.
Interview
The interviews were conducted by a research nurse
employed through Justice Health (i.e. the prison health
service, which is independent of the custodial authority).
The initial interview, adapted from that used previously
in the HITS-I study [22] recorded demographic charac-
teristics, and behavioral risk factors for HCV transmis-
sion (such as injecting behaviors, physical assaults or
injuries, tattooing and body piercing) over: the lifetime;
in the three months prior to current incarceration; and
in the period during the current incarceration (see Addi-
tional file 1: Appendix).
HCV serological and virological testing
A 10 ml venous blood sample was collected from each
inmate. HCV antibody testing was performed using the
qualitative Abbott ARCHITECT Anti-HCV chemilumi-
nescent microparticle immunoassay (Abbott Diagnostics,
A b b o t tP a r k ,I L ,U S A ) ,a n dc o n f i r m e de i t h e ru s i n gt h e
I N N O T E S TH C VA bI VE L I S Aa s s a y( I n n o g e n e t i c s ,
Gent, Belgium) or Monolisa™ HCV Ag-Ab ULTRA assay
(Bio-Rad Laboratories, Marnes-la-Coquette, France).
Qualitative HCV RNA detection was performed either
using the VERSANT HCV RNA Qualitative Transcrip-
tion Mediated Amplification (TMA) assay (Bayer Diag-
nostics, Emeryville, CA, USA; lower limit of detection:
3200 copies/ml) or COBAS AmpliPrep/COBAS TaqMan
H C Va s s a y( R o c h e ,B r a n c h b u r g ,N J ,U S A ;l o w e rl i m i to f
detection 223 copies/ml).
Data management
All interviews and HCV test results were entered into a
database created within SPSS for Windows (v. 17.0, Chi-
cago, IL, USA). A random sample of entered data (10%
of records) was checked by a study member not
involved in data collection or data entry, with a larger
data sample checked if the error rate was found to be
greater than 5%. Data entry errors were corrected prior
to statistical analyses.
Statistical analysis
Unadjusted HCV incidence rates were determined using
the person-years method with exact 95% Poisson confi-
dence intervals [23]. Different intervals of observation
were estimated according to HCV seroconversion status
in order to reliably attribute risk behaviors for HCV infec-
tion either to within-prison or outside-prison: firstly for
inmates who were HCV seropositive on the enrolment
test (regardless of whether they were HCV RNA positive
or negative), 42 days was added to the pre-enrolment anti-
HCV antibody negative test date to account for the period
prior to that date during which risk behaviors associated
with HCV transmission may have occurred, but was not
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estimated date of infection for these subjects was then
taken as the midpoint between the adjusted first and sec-
ond HCV test dates. Secondly, for inmates who were HCV
seronegative and RNA negative on the enrolment test, the
same adjustment for the first test date was made. Thirdly,
for inmates who were HCV RNA positive on the enrol-
ment test, but seronegative or antibody indeterminate on
that date, 14 days was subtracted from the enrolment
HCV test date to provide the estimated date of infection.
A corroborative incidence estimate was also calculated
based on the number of subjects who were viremic, but
seronegative. This estimate is based on an assumption
that in primary infection, viremia precedes seroconver-
sion by a median of 42 days, allowing incidence to be cal-
culated from cross-sectional data [25], according to the
following formula: I = (nvsn/Nsn) × (365/42) × (100);
where I = incidence per 100 py, n-vsn =n u m b e ro fH C V
RNA positive/seronegative subjects, Nsn =t o t a ln u m b e r
of seronegative subjects.
Incidence rates within the following subgroups were
determined: age at first test (18-25 years vs. >25 years),
gender, whether Aboriginal and/or Torres Strait Islander
(ATSI), whether continuously in prison for the duration
of observation (defined as having been incarcerated at
least 42 days prior to the initial HCV test until the time
of the second test), injecting drugs since most recent
entry into prison, having a tattoo, duration of injection
at pre-enrolment test (<5 years, 5-10 years, 10+ years),
predominant drug injected (heroin, methamphetamine,
cocaine, methadone/buprenorphine), sharing injecting
equipment, and whether currently receiving methadone
maintenance treatment (MMT). HCV incidence rates
within subjects who were of ATSI ethnicity were specifi-
cally examined, as this population is significantly over-
represented within the Australian custodial system, and
has a higher prevalence of blood borne viral infections
[26,27]. Subjects were designated as ATSI on the basis
of self-report during the enrolment interviews. In addi-
tion, incidence rates were determined for inmates who
were not continuously in prison during the period of
observation and who reported injecting drugs in the
three months prior to imprisonment, as this may have
contributed to incident infection within this sub-group.
Univariate associations between demographic and
behavioral risk factors for HCV infection were per-
formed using the c
2 statistic for categorical data or
unpaired two-tailed t tests for continuous data (SPSS for
Windows v. 17.0). Risk factors with trends towards asso-
ciations (p < 0.2) in the univariate analyses, in addition
to those previously reported in the published literature
were further investigated in multivariate logistic regres-
sion analysis using R [28] and SAS (v. 9.1; Cary, NC,
USA) statistical software packages.
Ethics
Ethical approval was obtained from Human Research
Ethics Committees of Justice Health (reference number
GEN 31/05), New South Wales Department of Corrective
Services (reference number 05/0884), and the University
of New South Wales (reference number 05094), all
located in Sydney, Australia.
Results
Demographics
The demographic characteristics of the 488 inmates are
shown in Table 1. The subjects were representative of
the general IDU inmate population, including a predo-
minance of young males (mean age 28 years) with rela-
tively low educational attainment (76% with less than 10
years of education), and a high rate of previous impri-
sonment (72%) and longstanding IDU (mean duration
8.5 years) with a high frequency of sharing behavior
(63%). Approximately one quarter of subjects reported
ongoing IDU since imprisonment (n = 133; 27%).
HCV incidence
Analysis of the enrolment blood samples identified 94
HCV incident cases (19% of the cohort) located in 17 of
the 19 recruiting correctional centers, including 51 men
(54%) and 43 women (46%). Eighty-five of these incident
cases (90%) had seroconverted, of whom 57 (67%) were
viremic; and another nine (10%) were viremic, but were
either antibody indeterminate or negative.
The overall HCV incidence rate was 31.6 per 100 per-
son years (100 py; 95% confidence interval 25.6-38.7).
The incidence rate based on seropositive subjects only
(N = 85) was 28.6 per 100 py (22.8-35.4). The corro-
borative incidence estimate based on the viremic, but
seronegative, case rate was 16.0 per 100 py (7.4-30.0).
Analysis of HCV incidence rates by selected demo-
graphic and behavioral subgroups (Table 2) showed that
the HCV incidence was significantly higher in subjects
Table 1 Demographic and behavioral characteristics of
subjects enrolled in the HITS cohort (n = 488)
Variable N = 488
Mean age; years (SD) 28 (6.9)
Male; No. (%) 318 (65)
Less than 10 years education; No. (%) 373 (76)
ATSI
†; No. (%) 121 (25)
Non-English speaking background; No. (%) 9 (2)
Previous imprisonment; No. (%) 352 (72)
Ever had a tattoo; No. (%) 354 (73)
Mean duration of IDU; years (SD) 8.5 (6.2)
Ever shared injecting equipment; No. (%) 306 (63)
IDU whilst in prison; No. (%) 133 (27)
† Aboriginal or Torres Strait Islander descent.
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subjects with ATSI background, though this did not
reach significance (p = 0.09). Incidence rates were signif-
icantly higher in those who reported: having been tat-
tooed (p = 0.01); IDU in the three months prior to
imprisonment (p <0 . 0 0 1 ) ,a n di nt h o s ew h ow e r e
receiving MMT (p < 0.001), including those who
reported injecting methadone (p = 0.05). Inmates who
had been continuously in prison had a lower incidence
(p = 0.04).
Demographic and behavioral risk associations with HCV
incident infection
Univariate analyses examined associations between HCV
incidence and demographic or behavioral risk variables
recorded in relation to the following time periods: ‘ever’;
‘in the three months prior to entry into prison’, and ‘since
entry into prison’ (Table 3). Significant positive associa-
tions were observed between incident HCV infection and:
a shorter duration of current imprisonment (mean 28 ver-
sus 52 weeks; p < 0.001); a higher frequency of previous
Table 2 HCV incidence rates in the HITS cohort stratified for demographic and behavioral risk variables (N = 488)
No. incident cases Incidence rate per 100 p.y. 95% CI
† Rate ratio
§ 95% CI
††
Total sample 94 31.6 25.6 - 38.7
Age at first HCV test
18 - 25 years 35 26.4 18.4 - 36.6 1.0
>25 years 59 35.9 27.3 - 46.3 1.4 0.9 - 2.1
Gender
Male 51 26.2 19.5 - 34.4 1.0
Female 43 42.0 30.4 - 56.5 1.6 1.1 - 2.4
Ethnic background
Other 68 29.2 22.7 - 37.0 1.0
ATSI 26 40.4 26.4 - 59.2 1.4 0.9 - 2.2
Continuously in prison
No 70 37.0 28.8 - 46.7 1.0
Yes 24 22.6 14.5 - 33.6 0.6 0.4 - 1.0
Ever had a tattoo
No 17 19.3 11.2 - 30.8 1.0
Yes 76 36.5 28.7 - 45.6 1.9 1.1 - 3.3
IDU in 3 months prior to imprisonment*
No 36 20.9 14.6 - 28.9 1.0
Yes 58 46.6 35.4 - 60.2 2.2 1.5 - 3.4
IDU since imprisonment
No 63 29.3 22.5 - 37.5 1.0
Yes 31 38.0 25.8 - 54.0 1.3 0.83 - 2.0
Duration of IDU
<5 years 21 24.3 15.0 - 37.1 1.0
5 - 10 years 43 36.6 26.5 - 49.3 1.5 0.9 - 2.6
>10 years 29 31.3 21.0 - 45.0 1.3 0.7 - 2.3
Main drug injected
Heroin 69 35.1 27.3 - 44.5 1.4 0.9 - 2.3
Methamphetamine 82 32.3 25.7 - 40.1 1.1 0.7 - 2.2
Cocaine 48 34.0 25.1 - 45.1 1.2 0.8 - 1.7
Methadone/buprenorphine 40 40.7 29.1 - 55.5 1.5 1.0 - 2.3
Sharing injecting equipment
No 31 30.0 20.3 - 42.5 1.0
Yes 63 33.8 26.0 - 43.3 1.1 0.7 - 1.8
Receiving MMT
No 58 24.6 18.6 - 31.7 1.0
Yes 36 60.1 42.1 - 83.2 2.5 1.6 - 3.7
† Poisson-exact 95% confidence intervals.
§ Figures in bold are significant at p < 0.05.
††. Exact method (mid-p).
* Only among inmates who were not continuously in prison included (n = 246).
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cases; p < 0.01); a longer duration of IDU (mean 9.5 versus
8.1 years; p = 0.04); ever having had a tattoo (81% of inci-
dent cases versus 71% of non-cases, p = 0.03), female gen-
der (46% versus 32%, p = 0.01), ever having ever injected
drugs either in prison or in a juvenile detention center
(52% versus 37%, p = 0.01), having ever had an injecting
frequency of daily or more (87% versus 75%, p = 0.01);
and receiving MMT at the time of the interview (38% ver-
sus 16%; p < 0.001). Injecting methadone was also signifi-
cantly associated with incident infection (43% vs. 32%, p =
0.046). Having injected drugs (83% versus 65%, p < 0.01);
injected daily or more often (71% versus 43%, p < 0.001);
and having always bleached shared equipment (19% versus
9%, p = 0.04) in the three months prior to incarceration
were also positively associated. Negative associations were
also observed, including continuous imprisonment during
the period of observation (26% versus 55%, p < 0.001),
having had a recent break from IDU (i.e. six months or
more without reported injecting) (35% versus 53%, p =
0.002), and having been injected by someone else (62%
versus 72%, p = 0.04).
The results of the multivariate logistic regression ana-
lysis are shown in Table 4. Independent positive
Table 3 Univariate analyses of demographic and risk behavior for incident HCV infection in the HITS cohort (n = 488)
Variable Incident cases (n = 94) Uninfected subjects (n = 394) p 95% CI
Mean age; years (SD) 28 (±7) 27 (±7) 0.08
Male gender; No. (%) 51 (54) 267 (68) 0.01 0.4 - 0.9
ATSI; No. (%) 26 (28) 92 (23) 0.38 0.8 - 2.1
Less than 10 years education; No. (%) 71 (76) 302 (77) 0.82 0.6 - 1.6
Duration of imprisonment; weeks (SD) 28 (±39) 52 (±95) <0.001
Previously imprisoned; No. (%) 79 (84) 276 (70) <0.01 1.2 - 4.1
Continuous imprisonment; No. (%) 24 (26) 216 (55) <0.001 0.2 - 0.5
Ever:
Mean duration of IDU; years (SD) (mean, years) 9.5 (±6.8) 8.1 (±6.0) 0.04
Tattoo; No. (%) 76 (81) 278 (71) 0.03 1.1 - 3.3
Body-piercing; No. (%) 68 (72) 307 (78) 0.25 0.4 - 1.2
Fight with blood; No. (%) 37 (39) 167 (42) 0.79 0.6 - 1.5
Stabbed; No. (%) 24 (26) 109 (28) 0.68 0.5 - 1.5
Shared a razor; No. (%) 12 (13) 66 (17) 0.39 0.4 - 1.5
Haircut with laceration; No. (%) 21 (22) 85 (22) 0.87 0.6 - 1.8
Blood contact during sport; No. (%) 12 (13) 80 (20) 0.11 0.3 - 1.1
Needle-stick injury; No. (%) 21 (22) 68 (17) 0.28 0.8 - 2.4
IDU in prison; No. (%) 49 (52) 147 (37) 0.01 1.1 - 2.8
Injected by someone else; No. (%) 58 (62) 284 (72) 0.04 0.4 - 1.0
Injected heroin; No. (%) 69 (73) 249 (63) 0.06 1.0 - 2.7
Injected methamphetamine; No. (%) 82 (87) 341 (87) 0.86 0.5 - 2.1
Injected methadone/buprenorphine; No. (%) 40 (43) 125 (32) 0.05 1.0 - 2.5
Daily IDU; No. (%) 82 (87) 296 (75) 0.01 1.2 - 4.3
Shared IDU equipment; No. (%) 63 (67) 243 (62) 0.43 0.8 - 2.0
Drug & Alcohol counseling; No. (%) 69 (73) 303 (77) 0.42 0.5 - 1.4
3 months prior to incarceration*
IDU; No. (%) 58 (83) 115 (65) <0.01 1.3 - 5.1
Daily IDU; No. (%) 50 (71) 75 (43) <0.001 1.9 - 6.1
Shared IDU equipment; No. (%) 18 (26) 41 (23) 0.69 0.6 - 2.2
Always bleach shared equipment, No. (%) 13 (19) 16 (9) 0.04 1.0 - 5.0
Since incarceration:
IDU; No. (%) 31 (33) 102 (26) 0.17 0.9 - 2.3
Daily IDU; No. (%) 3 (3) 15 (5) 0.56 0.2 - 2.4
Shared IDU equipment; No. (%) 27 (29) 93 (24) 0.30 0.8 - 2.2
Always bleach shared equipment, No. (%) 20 (21) 63 (16) 0.22 0.8 - 2.5
Recent break from IDU >6 months; No. (%) 33 (35) 208 (53) <0.01 0.3 - 0.7
Currently on MMT; No. (%) 36 (38) 63 (16) <0.001 2.0 - 5.3
* Only inmates who were not continuously in prison were included in this analysis (n = 246).
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tion and receiving MMT (p < 0.001) and previous impri-
sonment (p = 0.02). Positive associations were also
observed with having tattoos (p = 0.03), and with a fre-
quency of injecting of daily or more (p = 0.02) in the
three months prior to imprisonment.
In order to further explore the unexpected association
between incident infection and receiving MMT, the IDU
behaviors reported by inmates receiving MMT who
became incident cases and non-cases were compared
with those not receiving MMT (see Additional file 2).
The total group of inmates receiving MMT was more
likely to report having ever injected daily than those not
receiving MMT (p = 0.001); IDU since entry into prison
(p = 0.04); and sharing IDU equipment since entry into
prison (p = 0.08), suggesting more significant opioid
dependency (and hence the indication for MMT). Those
receiving MMT were also more likely to report a
‘decreasing’ pattern of IDU since entry into prison, than
those not receiving MMT (p = 0.01), suggesting the
treatment was likely to be favoring a reduction in inject-
ing behavior of those on treatment. However, inmates
receiving MMT were more likely to report injecting
methadone than those not receiving MMT (52% vs.
29%, p < 0.001), but this report was in relation to their
lifetime pattern, and was not continued while impri-
soned (p = 0.81).
Discussion
This study reports the largest number of incident HCV
cases identified in a longitudinal cohort of prison
inmates (n = 94). The overall HCV incidence rate (31.6
per 100 py) was higher than most previous reports
[11-15,18], potentially reflecting the specific inclusion of
inmates who reported a lifetime history of IDU. This
s u b s t a n t i v ec a s er a t ei sn o t e w o r t h ya st h ee n r o l l e d
population can reasonably be categorized as longstand-
ing and high risk IDUs with a mean duration of inject-
ing (8.5 years), and with sharing of IDU equipment
(63%), high rates of tattooing (73%), and prior imprison-
ment (72%) - each of which has been independently
associated with the risk of HCV infection. Thus, this
group appears to have been at high risk of HCV infec-
tion over a prolonged period, but have remarkably
remained seronegative, and yet have a high rate of inci-
dent infection associated with incarceration. This high
incidence may relate to changes in specific IDU beha-
viors in the unstable period both prior to, and immedi-
ately following, incarceration. Indeed, in both the
univariate and logistic regression analyses, stronger asso-
ciations were found with risk behaviours, such as IDU
and sharing reported in the three months prior to
imprisonment, than those ‘since imprisonment’. Further,
it is plausible that there is a causative relationship relat-
ing to drug availability, imprisonment and incident
Table 4 Associations between demographic and behavioral characteristics and HCV incident case status using logistic
regression analysis (n = 488)
Variable Odds ratio 95% CI p
Age >25 years 1.29 0.69 - 2.43 0.43
Male gender 0.75 0.41 - 1.39 0.37
ATSI 1.36 0.73 - 2.53 0.33
Previously imprisoned 2.45 1.18 - 5.11 0.02
Continuously in prison 0.68 0.27 - 1.62 0.41
Duration of imprisonment (weeks) 0.93 0.73 - 1.20 0.60
Ever had a tattoo 2.01 1.01 - 4.01 0.05
Duration of IDU (years) 1.27 0.84 - 1.92 0.26
Ever shared IDU equipment 1.34 0.69 - 2.62 0.39
Ever daily IDU 0.77 0.34 - 1.76 0.53
Ever injected heroin 0.76 0.39 - 1.48 0.42
Ever injected methadone/buprenorphine 1.20 0.63 - 2.29 0.57
Ever IDU in prison 0.87 0.37 - 2.04 0.74
Ever injected by someone else 0.62 0.34 - 1.14 0.12
IDU in 3 months prior to imprisonment* 0.93 0.31 - 2.78 0.89
Daily IDU in 3 months prior to imprisonment* 3.70 1.36 - 10.10 0.01
Always bleached IDU equipment in 3 months prior to imprisonment* 0.38 0.1 - 1.39 0.14
IDU since imprisonment 1.87 0.37 - 9.46 0.45
Shared IDU equipment since imprisonment 0.91 0.18 - 4.48 0.91
Recent break from IDU (>6 months) 0.90 0.47 - 1.70 0.74
Receiving MMT 3.13 1.66 - 5.91 <0.001
* Only inmates who were not continuously in prison were included in this analysis (n = 246).
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iations in drug supply may prompt the illegal acts which
lead to arrest and imprisonment, and incident HCV
infection in this period.
The cohort included IDU inmates who had been con-
tinuously imprisoned and those who had been both out-
side and inside prison during the period of surveillance.
A preliminary analysis of a subset of the inmates
reported here, who were continuously in prison (n =
120) has been described elsewhere [29], which revealed
an incidence of 34.2 per 100 py. This estimate is some-
what higher than the incidence of those continuously
imprisoned in the current analysis (22.6 per 100 py).
In previous studies of IDU in the community, predic-
tors of HCV seroconversion have included: reporting
injecting in the previous six months, and more than daily
IDU [3]; a duration of injecting of less than one year and
injecting cocaine [30,31], sharing needles [3,30,32] and
sharing other injecting paraphernalia [3,32,33], being of
female gender, and having a culturally and linguistically
diverse background (CALD) [31]. Among new IDUs with
a CALD background in Australia, HCV seroconversion
was strongly associated with sharing syringes, and other
injecting equipment [31]. By contrast, the only previous
study of IDU prisoners with sufficient numbers of inci-
dent cases to allow risk assessment, revealed associations
with older age, tattooing in prison, and injecting heroin
[16]. Perhaps surprisingly therefore, this study found
modest associations between the incidence of HCV infec-
tion and specific IDU behaviors in prison inmates with
only IDU in the three months prior to imprisonment
being associated with incident infection. The possible
explanations for this outcome may firstly include under-
reporting of actual IDU and sharing behaviors due to the
difficulties in accurate recollection of specific IDU epi-
sodes over several months prior to the interview - this
m a yb ec o n s i d e r e du n l i k e l ya sm o r et h a nh a l fo ft h e
group reported daily IDU. Secondly, there may be limita-
tions in the reporting of information relating to risk
behaviors occurring in prison, as both IDU and tattooing
are illegal - nevertheless the interviews were conducted
in private and by research staff employed in the Justice
Health Service, which is independent of the custodial
authority.
Although consistent with previous reports [7,8,18], the
associations between incident infection and lifetime his-
tories of prior imprisonment and tattooing reported
here, are unlikely to be direct as the subjects were
found to be seronegative at screening. By contrast, it is
likely that these variables act as surrogates for more
recent risk behaviors potentially associated with HCV
transmission. Thus, it is possible that there are addi-
tional risk behaviors relating to IDU (such as back-load-
ing [4]), or other blood-to-blood events not adequately
explored in the interview schedule. For instance, the
enrolment interview did not include detailed investiga-
tion of recent tattooing episodes, fights, and other par-
enteral blood contacts. These events are being sought in
the follow-up interviews in the HITS cohort.
The strong association observed in the data reported
here between HCV incidence and MMT has not pre-
viously been reported. This association may be attributa-
ble to injecting the dispensed drug rather than ingesting
the dose (despite being supervised), as the rates of
reported injecting of methadone were significantly
higher in incident cases compared to non-cases. It was
also noteworthy that approximately half of the inmates
receiving MMT reported a lifetime pattern of injecting
methadone, whereas only approximately a third of those
not receiving MMT reported this behavioral risk. How-
ever, this report was not sustained in prison, raising the
possibility of under-reporting of methadone injecting by
those receiving MMT whilst in prison.
Another limitation in relation to this finding is that
methadone treatment status at the time of the initial
negative HCV test result may not have been the same as
that recorded at enrolment. It is possible that the inci-
d e n tc a s e s( n=3 6 )a n dn o n - c a s e s( n=6 3 )o nM M T
differed in the continuity of that treatment and hence
the likelihood of associated risk behaviors, although the
mean methadone dose and the reported number of
missed doses did not differ between these subgroups
(data not shown). It is also possible that MMT uptake
in prison is greater among individuals who are at higher
risk of HCV infection. Consistent with previous reports
[16,17], there was evidence that MMT was generally
associated with a reduced frequency of IDU and sharing.
The positive association between MMT and HCV inci-
dence therefore warrants further investigation. For
instance, continuous recording of dosages and periods
of cessation of MMT may be informative. The generaliz-
ability of the MMT association finding should also be
taken with caution, given the likely variations in HCV
incidence and clear differences in MMT policies in
prison settings internationally [34].
One of the mainstays of the prevention strategies for
blood borne virus transmission in this prison setting is
the provision of bleach (1% hypochlorite solution) and a
recommended protocol (a repeated water rinse following
by repeated bleach rinse, followed by repeated water
rinse) for cleansing of injecting apparatus. Previous
reports have raised concerns that although this disinfec-
tion method is likely to reduce HIV transmission, it may
be less effective for HCV [14,35-38]. Consistent with
this concern, there was no apparent reduction in HCV
incidence among individuals who reported IDU and
sharing, but who indicated that they always bleach-
cleansed the injecting apparatus.
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The findings reported here raise concerns that impri-
sonment of IDUs is associated with an unacceptably
high risk of acquisition of HCV infection, in particular
in the period surrounding imprisonment. Further inves-
tigation of the specific circumstances in which transmis-
sions are occurring is warranted to guide effective
prevention strategies, such as introduction of profes-
sional tattooists and needle-syringe exchange programs
in prison.
Additional material
Additional file 1: Appendix - Hepatitis C Incidence and Transmission
in Prisons Study (HITS-II) Enrolment Interview. Questionnaire
document
Additional file 2: IDU behaviors amongst inmates receiving MMT.
Table of frequencies and univariate comparisons
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